Ketamine-Prazosin Combined Pharmacotherapy in Post-Traumatic Stress Disorder and Alcohol Use Disorder: Targeting Complementary Neurobiological Mechanisms.

Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) frequently co-occur, leading to worse outcomes and higher relapse rates. Ketamine can produce rapid and lasting reductions in PTSD symptoms and AUD relapse. Prazosin effectively treats PTSD-related nightmares and may lower alcohol consumption in people with high autonomic reactivity. Because these drugs work through complementary mechanisms—modulating glutamatergic transmission and reducing noradrenergic hyperactivity—combining them may improve stabilization, readiness for trauma-focused therapy, and broader symptom control. Although this combination has not been tested in clinical trials, it warrants nurse practitioner-led research to evaluate safety, efficacy, and integration into multidisciplinary care.

Study at a glance

Abstract

Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) often co-occur, worsening outcomes, relapse rates, and treatment response. Ketamine produces rapid and sustained PTSD symptom reduction and reduces AUD relapse. Prazosin effectively treats PTSD-related nightmares and may reduce alcohol consumption in individuals with heightened autonomic reactivity. The dual complementary mechanisms, modulation of glutamatergic neurotransmission and attenuation of noradrenergic hyperactivity, provide a compelling rationale for combination pharmacotherapy. Potential benefits include improved stabilization, readiness for trauma-focused therapy, and broader symptom control. Although untested in clinical trials, this approach warrants nurse practitioner-led research to evaluate safety, efficacy, and integration into multidisciplinary care.